GUIDANCE DOCUMENT
Draft
Not for implementation. Contains non-binding recommendations.
This guidance is being distributed for comment purposes only.
Submit Comments by
Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the FDA considers your comment on a draft guidance before it begins work on the final version of the guidance, submit either online or written comments on the draft guidance before the close date.
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2024-D-5663
- Docket Number:
- FDA-2024-D-5663
- Issued by:
-
Guidance Issuing Office
Oncology Center of Excellence
This guidance provides recommendations to sponsors for the clinical development of drug and biological products intended for the prevention and treatment of chemotherapy-induced peripheral neuropathy in oncology patient populations. The guidance pertains to development programs for drugs regulated by the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.
